Biotech Stocks Under Scanner -- Mast Therapeutics, MannKind, Celgene, and Opko Health

NEW YORK, February 3, 2017 /PRNewswire/ --

Today's attention is redirected to the Biotech space which is engaged in the research and development of biological substances, primarily for the purpose of drug discovery and diagnostic development. The majority of Biotechnology companies' revenue is derived from either the sale or licensing of drugs and diagnostic tools. Pre-market, Stock-Callers.com presents the following stocks for evaluation: Mast Therapeutics Inc. (NYSE MKT: MSTX), MannKind Corp. (NASDAQ: MNKD), Celgene Corp. (NASDAQ: CELG), and Opko Health Inc. (NASDAQ: OPK). You can access our complimentary research reports on these stocks now at:

http://stock-callers.com/registration

Mast Therapeutics  

California headquartered Mast Therapeutics Inc.'s shares declined 1.38%, closing Thursday's trading session at $0.13. The stock recorded a trading volume of 3.07 million shares. Shares of the Company have surged 28.20% in the last month, 83.14% over the previous three months, and 42.44% since the start of this year. The stock is trading 15.29% above its 50-day moving average. Additionally, shares of Mast Therapeutics, which develops therapies for serious or life-threatening diseases with significant unmet needs, have a Relative Strength Index (RSI) of 54.19.

On January 07^th, 2017, Mast Therapeutics and Savara announced that the two companies have entered into a definitive merger agreement, under which Savara's stockholders will receive newly issued shares of Mast's common stock in exchange for their Savara's stock. The exchange ratio was determined using a pre-transaction valuation of $115 million for Savara's business, based on its latest priced investment round and an acquisition of assets of Serendex Pharmaceuticals A/S, and $36.5 million for Mast's business, a premium to the 20-day volume weighted average share price of Mast. As a result, current Mast's stockholders will collectively own approximately 24%, and Savara's stockholders will collectively own approximately 76%, of the combined company on a pro-forma basis. Visit us today and download your complete report on MSTX for free at:

http://stock-callers.com/registration/?symbol=MSTX

MannKind  

On Thursday, shares in California headquartered MannKind Corp. recorded a trading volume of 14.84 million shares, which was above their three months average volume of 5.27 million shares. The stock plummeted 17.14%, ending the day at $0.59. The Company's shares have advanced 33.05% in the previous three months. The stock is trading below its 50-day moving average by 7.78%. Furthermore, shares of MannKind, which focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the US, have an RSI of 42.23.

On February 01^st, 2017, MannKind announced the launch of a new Titration Pack containing 60 - 4 unit cartridges, 60 - 8 unit cartridges and 60 - 12 unit cartridges of Afrezza (insulin human) Inhalation Powder. The Company stated that the new package is intended to simplify physician prescribing of Afrezza and allow patients greater dose flexibility in managing their diabetes, while potentially reducing the cost burden of multiple copays. The complimentary research report on MNKD can be accessed at:

http://stock-callers.com/registration/?symbol=MNKD

Celgene  

Summit, New Jersey headquartered Celgene Corp.'s stock finished the day 1.59% lower at $115.54 with a total trading volume of 4.24 million shares. The Company's shares have gained 11.00% in the previous three months. The stock is trading above its 200-day moving average by 6.33%. Additionally, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have an RSI of 49.59.

On January 27^th, 2017, Celgene International Sàrl, a wholly owned subsidiary of Celgene, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the use of REVLIMID® as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma that have undergone autologous stem cell transplantation. Once approved by the European Commission, REVLIMID® will be the first and only licensed maintenance treatment available to these patients. Register for free on Stock-Callers.com and download the PDF research report on CELG at:

http://stock-callers.com/registration/?symbol=CELG

Opko Health  

Shares in Miami, Florida headquartered Opko Health Inc. ended yesterday's session 1.39% lower at $8.51 with a total trading volume of 2.42 million shares. The stock is trading 14.80% below its 200-day moving average. Shares of the Company, which engages in the discovery, development, and commercialization of novel and proprietary technologies in the US, Ireland, Chile, Spain, Israel, and Mexico, have an RSI of 36.61.

On February 01^st, 2017, OPKO announced that its subsidiary and business unit, GeneDx, is entering into a collaboration with the Deciphering Developmental Disorder (DDD) study led by the Wellcome Trust Sanger Institute. The DDD study aims to determine the clinical utility of leveraging advanced genomic technologies to diagnose patients with developmental disorders. This will be accomplished in two ways: (i) identifying novel genes and pathways for human genetic diseases and characterizing the associated phenotypes; and (ii) improving informatics and statistical methods to robustly diagnose patients with genetic condition. Get free access to your research report on OPK at:

http://stock-callers.com/registration/?symbol=OPK

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number:+44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA